Here, we show the ability of midostaurin to rapidly and potently inhibit the in vivo growth of mutant CBL‐positive leukaemia cells in two distinct models, highlighting the potential for FLT3 inhibitors like midostaurin that are approved and are in current clinical use for patients with aberrant FLT3 signalling. Here, FLT3 is linked to leukemia.